Two new studies from the Pneumococcal Awareness Council of Experts highlight the increased risk for children in Africa of contracting pneumococcal disease and suffering its devastating consequences. The studies were presented at the USA-based Sabin Vaccine Institute's Fourth Regional Pneumococcal Symposium in Johannesburg, South Africa. According to the PACE, the findings reinforce the urgent need for improving access to life-saving vaccines and treatments throughout the continent. The South African Ministry of Health was congratulated for its leadership in making South Africa the first country in Africa to introduce pneumococcal vaccine (Marketletter September 21, 2008)
Cirode Quadros, executive vice president of the Sabin Vaccine Institute and co-chairman of the PACE, said: "in light of the risks and devastating consequences of pneumococcal disease, particularly in Africa, protecting African children from this disease is an urgent priority. We urge countries in Africa and throughout the developing world to follow South Africa's example and ensure vaccines are available to those that need them most."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze